

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	infliximab
Brand Name	Inflectra™
Dosage Form(s)	100 mg vial
Manufacturer	Pfizer Canada Inc.
Submission Review	New Submission
Use Reviewed	Rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and plaque psoriasis (PsO).
Common Drug Review (CDR)	Yes, CDR recommended: to List with criteria . Visit the CDR website for more details: www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_SE0384_Inflectra_Dec-23-14.pdf .
Drug Benefit Council (DBC)	DBC met on January 12, 2015. DBC considered various inputs including: final review completed by the CDR on December 19, 2014, which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC). The DBC also considered Clinical Practice Reviews from two specialists, as well as a Budget Impact Assessment (BIA) and patient input from three patients and three patient groups.
Drug Coverage Decision	Limited Coverage Benefit . Access the infliximab (Inflectra™) criteria from www.gov.bc.ca/pharmacarespecialauthority
Date	February 19, 2016
Reason(s)	<p>Drug coverage decision is consistent with the CDEC and DBC recommendations.</p> <ul style="list-style-type: none"> • Inflectra™ is a subsequent entry biologic (SEB) or “biosimilar” version of infliximab based upon the reference product Remicade®. It was approved by Health Canada and supported by the CDR for RA, AS, PsA and PsO based upon data demonstrating similarity and no meaningful differences compared to the reference product. • Based on the available evidence, Inflectra™ is similar to Remicade with respect to efficacy, safety and pharmacokinetics profile in patients with RA and AS and, by extrapolation, in patients with PsA and PsO. • At the submitted price, the cost of Inflectra is lower than the cost of Remicade®. • Pan-Canadian Pharmaceutical Alliance negotiated a lower transparent price that is available to all, public and private payers.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) (DBC) gives advice to the Ministry. The DBC looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C.
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the DBC
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

Visit the B.C. [Drug Review Process](#) and [PharmaCare](#) program for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.